Skip to main content

COVID-19 and the Rise of Digital Pathology

Join us for a special presentation on COVID-19 and the Rise of Digital Pathology
Wednesday, October 21, 2020
11:00 AM – 12:00 PM PDT
2:00 PM – 3:00 PM EDT

Leica Biosystems is proud to present this complimentary webcast with Dr. Eric Glassy, a renowned speaker on Digital Pathology and Dr. Matthew Hanna, Director of Digital Pathology Informatics at Memorial Sloan Kettering Cancer Center.

A week after the declaration of a national emergency, the Centers for Medicare and Medicaid Services (CMS) temporarily lifted the CLIA license requirement for the sign-out of pathology cases at remote locations. The FDA also exercised regulatory enforcement discretion regarding how digital pathology systems could be marketed. Many pathologists took advantage of the sign-out flexibility to minimize COVID-19 exposure risks and provide timely diagnoses.

Digital pathology rose to the occasion and delivered on its promise of performing diagnoses from anywhere. But even in the face of a pandemic, it is important that digital pathology systems be properly implemented and validated. This session will review the regulatory issues around remote sign-out and then dive into the digital pathology system components and laboratory operation considerations to initiate a digital workflow.

We will also explore the clinical validation that was performed at Memorial Sloan Kettering Cancer Center that allowed pathologists to offer remote clinical reporting. Finally, we’ll emphasize the importance of actively engaging with our clinical and surgical colleagues, especially when working remotely.

The information presented represents the opinion of the presenters and is not necessarily the view of USCAP. USCAP does not endorse the products or services. The webinar was made possible through a sponsorship from Leica Biosystems. This activity is not available for CME.